Clinical Trials

Clinical cancer research is at the heart of everything we do at the Cancer Research & Treatment Fund. As a service to health professionals and the public, CR&T provides a brief listing of significant sites that are concerned with trials at institutions throughout the United States.

Unless otherwise indicated, these experimental clinical trials are currently recruiting patients. Studies closed to accrual are also included, since follow-up trials open to accrual may be in the planning stage or may be in progress at other medical centers.

All active cancer protocols are being carried out concurrently at various other medical centers across the country. The great majority of the trials are sponsored either by the federal government (through the National Cancer Institute or its Cancer and Leukemia Group B) or by pharmaceutical corporations.

Trials are categorized by phase, which indicates how far an experimental drug or treatment has progressed:

  • Phase-I Trials – Researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. The dosage may start low and then increase.
  • Phase-II Trials - The study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
  • Phase-III Trials - The study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

A perusal of clinical trial sites indicates that a wide variety of agents and treatments are being tested including;

  1. Chemotherapeutic drugs that interfere with basic cellular processes
  2. Molecule-targeting drugs, such as Gleevec, which hone in on aberrant proteins or genes that make cells cancerous
  3. Monoclonal antibodies or other biological agents that target aberrant proteins or genes that make cells cancerous
  4. Treatments that stimulate the body’s immune system to attack cancers.

Clinical Trial Resources